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Abstract
NutramilTM Complex is a multicomponent food product that meets the requirements of a
food for special medical purpose. As a complete, high-energy diet it consists of properly bal-
anced nutrients, vitamins and minerals. The aim of this study was to assess the effect of
NutramilTM Complex on breast and prostate carcinoma cells. Our results showed that Nutra-
milTM Complex reduced the viability and proliferation of breast and prostate cancer cells and
that this process was associated with the induction of apoptosis via activation of caspase
signalling. Data showed elevated levels of p53 tumour suppressor, up-regulation of p38
MAPK and SAPK / JNK proteins and downregulation of anti-apoptotic ERK1/2, AKT1 and
HSP27. Treatment with NutramilTM Complex also affected the expression of the BCL2 fam-
ily genes. Results also showed down-regulation of anti-apoptotic BCL-2 and up-regulation
of pro-apoptotic members such as BAX, BAD, BID. In addition, we also observed regulation
of many other genes, including Iκβα, Chk1 and Chk2, associated with apoptotic events.
Taken together, our results suggest activation of the mitochondrial apoptotic pathway as
most likely mechanism of anti-carcinogenic activity of NutramilTM Complex.
Introduction
Breast cancer is one of the most common type of cancer affecting women around the world
[1], and is also the leading cause of cancer death in the female part of the population [2]. Pros-
tate cancer, on the other hand, occupies the third place of type of cancer for males, and fourth
place as the cause of cancer deaths [3]. Although improving diagnostic tools helps with the
patients’ outcome, research in cancer prevention remains insufficient.
Numerous studies showed that selected nutrients and non-nutrients can act preventively in
cancer. They included, among others, diets rich in vegetables (i.e. cruciferous vegetables, toma-
toes), fruits, oily sea fish and soybeans; thus, rich in vitamin E, C, carotenoids (beta-carotene,
lycopene) selenium, omega-3 fatty acids, glucosinolates, polyphenols and etc. [4–6].
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NutramilTM Complex is a Food for Special Medical Purpose (FSMP), intended for people
whose nutritional requirements cannot be met by normal food, which follows the European
Union Directive 1999/21/EC regarding its composition and levels of vitamins and minerals. It
can be used as a complete, all-day meal for the hospitalised patient, or used as a supplement.
The choice depends on nutritional status, individual energy needs, ability to take other meals
as well as general health or disease progression. NutramilTM Complex is also used to prevent
malnutrition in associated with lack of appetite, anorexia, Alzheimer’s disease, Parkinson’s dis-
ease, cancer, irritable bowel syndrome, partial gastric or intestinal resection, etc. In addition, it
is also gluten- and lactose-free.
In our pilot studies, NutramilTM Complex has decreased the viability of breast and prostate
cancer cells [7, 8]. To our knowledge, there are no other reports showing NutramilTM anti-can-
cer properties as a multi-component product. However, limited data is available on some indi-
vidual substances that constitutes the composition of NutramilTM Complex. In this
manuscript, we present the effect of NutramilTM Complex on breast and prostate carcinoma
cells. Our results suggest that observed reduction in viability of cancer cells can be associated
with induction of apoptosis.
Materials and methods
Testing material
Composition of the NutramilTM Complex (NC) is given in the S1 Table. To determine the
effect of complete compound on cancer cells, two additional compounds were investigated: an
incomplete NutramilTM Complex without calcium caseinate (NC-CC) and calcium caseinate
alone (CC) as one of the main components of the formulation. Analyses were blinded as all
samples were numerically encoded. Their decoding took place at the end of the study.
Cell culture
The human breast adenocarcinoma cell line MCF-7 (estrogen receptor (ER) positive cell line,
progesterone receptor positive and HER2 negative, ATCC1 HTB22TM) was purchased from
the American Type Culture Collections. Cells were cultured in appropriate EMEM medium
(Sigma-Aldrich, MO, USA) according to the ATCC protocol with an addition of 10% FBS
(Sigma-Aldrich, MO, USA).
The human prostate carcinoma DU145 (not detectably hormone sensitive, ATCC1 HTB-
81TM) and LNCaP cell lines (androgen receptor, positive; estrogen receptor, positive; ATCC1
CRL-1740™) were purchased from the American Type Culture Collections. Cells were cultured
in appropriate EMEM and RPMI 1640, respectively, medium (Sigma-Aldrich, MO, USA)
according to the ATCC protocol with an addition of 10% FBS (Sigma-Aldrich, MO, USA).
The human normal prostate PNT-2 cell line was purchased from HPA Culture Collections
(Sigma-Aldrich, MO, USA). Cells were cultured in appropriate RPMI 1640 medium (Sigma-
Aldrich, MO, USA) according to the protocol with an addition of 10% FBS (Sigma-Aldrich,
MO, USA).
Cell treatment
Cells were seeded on 96-well plates (8x103 cells per well), 12-well plates (9x104 cells per well)
or 6-well plates (2x105 cells per well). 24 h after seeding, growth medium was replaced with a
medium containing: 1) NC, 2) NC-CC or 3) CC. The final applied concentrations of each
treatment were 1, 2, 3, 4, 5 and 10% for 24, 48 and 72 h. Untreated cells in culture medium
were used as a negative, untreated control (UC).
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For apoptosis assessment, Staurosporine (Sigma-Aldrich, MO, USA) was used as a positive
control at the final concentration of 1.5 μM.
Cytotoxicity and cell viability
Cell viability was determined by Crystal Violet Assay (Sigma-Aldrich, MO, USA) and Cytotox-
icity Detection Kit LDH (Roche, Poland) according to the manufacturer’s protocol.
Each treatment included 3 biological and 4–5 technical replicates.
Cell proliferation assessment
Cell proliferation was determined with 5’-bromo-2’-deoxy-uridine (BrdU) Labeling and
Detection Kit III (Roche), according to manufacturer’s instruction.
Each treatment included 3 biological and 3 technical replicates.
RT and Real-time PCR analysis
Reverse transcription was performed using 1 μg of total RNA isolated from the cells using the
Maxima first Strand cDNA Synthesis kit for RT-qPCR (Thermo Scientific). A quantitative verifi-
cation of genes was performed with TaqMan1 Array Human C-MYC and Apoptosis (Thermo
Fisher Scientific) according to the manufaturer’s protocol and StepOnePlus™ system. Analysed
genes: AKT1, APAF1, BAD, BAX, BCL2, BID, CASP3, CASP8, CDKN2A, CYCS, FADD, FAS,
FASLG, HRAS, IGF1, IGF1R, KRAS, MYC, NRAS, RRAS, TP53, YWHAB, YWHAE, YWHAG,
YWHAH, YWHAQ, YWHAZ. Results were normalized using at least two reference genes (18S,
GAPDH, HPRT1or GUSB) and were calculated using the 2-ΔΔCT method [9].
Stress and apoptosis signalling assay
Cell extracts were prepared and analyzed using the PathScan1 Stress and Apoptosis Signaling
Antibody Array Kit (Chemiluminescent Readout) #12856, Cell Signaling Technology, MA,
USA. Assay target proteins were P44/42 MAPK (ERK1/2) phosphorylation, AKT phosphoryla-
tion, BAD phosphorylation, HSP27 phosphorylation, SMAD2 phosphorylation, p53 phos-
phorylation, p38 MAPK phosphorylation, SAPK/JNK phosphorylation, PARP cleavage,
Caspase-3 cleavage, Caspase-7 cleavage, total Ikβα, Chk1 Ser345 phosphorylation, Chk2 phos-
phorylation, Ikβ α phosphorylation, eIF2α phosphorylation, TAK1 phosphorylation, Survivin
and α-Tubulin as a reference protein.
Images were acquired by briefly exposing the slide to standard chemiluminescent film.
Densitometry analysis was performer using ImageJ (http://imagej.nih.gov/ij/). Results are
shown as a mean±SD normalized to the internal reference protein (α-Tubulin). Untreated
negative control (UC) was set as 100% expression level.
Western blot assay
Whole cell lysis was carried out using Cell Lysis Buffer (Cell Signaling Technology, MA, USA)
according to the manufacturer’s protocol, with the addition of Protease Inhibitor Cocktail
(BioShop, Canada). Total protein was quantified with Pierce BCATM Protein Assay Kit
(Thermo Fisher Scientific, MA, USA). Protein extract was separated on a polyacrylamide gel
and transferred to a nitrocellulose filter (Bio-Rad, CA, USA) by wet-electroblotting. Subse-
quently, the immobilized proteins were incubated with the appropriate primary antibody:
cytochrome c (#11940), Smac/Diablo (#2954), HtrA2/Omi (#9745) and β-Tubulin (#2128)
(Cell Signaling Technology, MA, USA). Finally, the appropriate secondary antibody conju-
gated with horseradish peroxidase (#7074, Cell Signaling Technology, MA, USA) was applied.
Effect of “NutramilTM Complex” on breast and prostate carcinoma cells
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Detection was executed by chemiluminescence, using Clarity™ Western ECL Substrate (Bio-
Rad, CA, USA). Western blot stripping buffer (Thermo Scientific, MA, USA) was used to
remove the antibodies from the membrane.
Statistical analysis
All experiments were performed in at least three independent experiments and measured in
triplicates. Shapiro-Wilk’s test was applied to assess normality of distribution. An independent
samples t-test was applied to compare unpaired means between two groups and P0.05 was
considered statistically significant. All analyses were performed using Statistica ver.12 (Stat-
Soft, Tulsa, OK, USA).
Results
Cytotoxicity
NutramilTM Complex showed a cytotoxic effect on all examined cells, both cancer and non-
malignant in a dose–and time–dependent manner (Table 1). Cytotoxicity levels for NC-CC
were lower than those observed for NC (Table 1). All cell lines showed mostly necrotic changes
at 10% concentration of NC (Table 1). The cytotoxicity results for treatment with 5% NC was
Table 1. Cytotoxicity of NutramilTM Complex.
Concentration DU145 Cytotoxicity % LNCaP Cytotoxicity % MCF-7 Cytotoxicity % PNT-2 Cytotoxicity %
NC vs UC
± SD
NC-CC vs UC ± SD NC vs UC
± SD
NC-CC vs UC ± SD NC vs UC
± SD
NC-CC vs UC ± SD NC vs UC
± SD
NC-CC vs UC ± SD
24 h
1% 0,04 ± 0,20 Nt 2,88 ± 0,51 Nt 4,69 ± 1,21 Nt 4,26 ± 0,39 Nt
2% 2,08 ± 0,80 Nt 5,46 ± 1,61 3,10 ± 1,33 5,86 ± 0,81 Nt 5,98 ± 0,39 Nt
3% 6,18 ± 0,40 3,10 ± 0,33 8,55 ± 1,11 1,15 ± 0,84 8,41 ± 0,83 9,15 ± 0,88 10,75 ± 4,10 1,67 ± 0,90
4% 9,67 ± 1,47 1,15 ± 0,84 11,24 ± 0,83 4,20 ± 1,22 12,41 ± 0,67 9,83 ± 0,92 13,30 ± 2,27 1,06 ± 0,14
5% 15,21 ± 1,33 4,20 ± 1,22 15,47 ± 2,33 Nt 18,04 ± 2,27 12,99 ± 0,73 15,16 ± 2,54 1,48 ± 0,52
10% 28,34 ± 2,06 Nt 30,22 ± 6,25 Nt 20,70 ± 1,24 Nt 29,11 ± 7,50 Nt
48 h
1% 0,70 ± 0,10 Nt 2,76 ± 2,74 Nt 3,61 ± 2,06 Nt 2,45 ± 2,99 Nt
2% 1,69 ± 0,36 Nt 5,97 ± 7,14 Nt 4,07 ± 0,80 Nt 2,31 ± 2,06 Nt
3% 7,52 ± 1,57 6,81 ± 1,73 7,70 ± 3,19 6,62 ± 0,34 6,36 ± 1,66 7,48 ± 1,60 9,84 ± 3,80 2,48 ± 0,23
4% 10,24 ± 1,89 7,88 ± 0,46 8,06 ± 1,25 6,38 ± 0,75 9,12 ± 3,03 8,72 ± 2,50 19,68 ± 12,29 3,71 ± 0,16
5% 13,83 ± 1,78 11,60 ± 2,24 11,30 ± 1,92 4,53 ± 0,40 10,00 ± 0,52 11,35 ± 1,25 22,64 ± 11,33 2,04 ± 0,95
10% 36,97 ± 4,32 Nt 22,68 ± 3,75 Nt 18,22 ± 7,37 Nt 44,23 ± 12,89 Nt
72 h
1% 0,58 ± 0,04 Nt 0,81 ± 2,39 Nt 3,93 ± 2,45 Nt 1,79 ± 0,77 Nt
2% 0,12 ± 0,83 Nt 1,80 ± 2,38 Nt 5,03 ± 3,14 Nt 1,13 ± 0,35 Nt
3% 4,00 ± 0,19 1,28 ± 0,86 7,18 ± 2,40 7,29 ± 0,55 7,03 ± 4,26 5,61 ± 1,18 5,46 ± 0,88 3,81 ± 0,33
4% 8,08 ± 1,24 2,85 ± 0,18 8,90 ± 5,29 4,88 ± 0,67 7,16 ± 3,50 5,14 ± 1,23 5,01 ± 1,13 4,25 ± 1,17
5% 18,78 ± 2,16 6,72 ± 1,59 11,55 ± 6,95 4,28 ± 0,28 9,59 ± 6,34 7,03 ± 1,49 6,56 ± 1,37 2,98 ± 1,45
10% 42,75 ± 4,16 Nt 27,74 ± 8,53 Nt 27,92 ± 6,99 Nt 21,07 ± 5,12 Nt
MCF-7 breast cancer cells; DU145 and LNCaP prostate cancer cells; PNT-2 normal cancer cells were seeded on the 96-well plates (8x103 cells per well). 24 h after,
growth medium was replaced with a medium containing “NutramilTM Complex” and “NutramilTM Complex” without calcium caseinate (1–10% of concentration, 24–
72 h). Cytotoxicity was measured with Cytotoxicity Detection Kit LDH (Roche, Poland). Values are expressed as mean ± SD for n = 15, standardized to untreated
control (UC) as 100%. Nt, no treatment.
https://doi.org/10.1371/journal.pone.0192860.t001
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at approximately 15% of UC after 24 hrs for all cell lines. Based on those results, all further
experiments were performed using 4% concentration for NC as well as NC-CC, that lowered
proliferation but did not caused a significant necrosis to cells.
Cell viability
Treatment with 4% NutramilTM Complex decreased the viability of MCF-7 breast cancer cell
line by 20% after 24–48 h and by 35% after 72 h (P0,001; Fig 1A). Results for NC-CC showed
a similar trend, while CC showed quite the opposite—significant increase in the MCF-7 cells
viability (P0.001; Fig 1A).
Treatment with 4% NutramilTM Complex also decreased the viability of prostate cancer
cells by 30% after 48 h and by 70% after 72 h (P<0,001, Fig 1B and 1C). The results did not dif-
fer significantly between androgen-independent DU145 cell line and androgen-dependent
LNCaP. On the other hand, NC treatment increased significantly the viability of the normal
prostate cells PNT-2 after 24–48 h to 150% of the UC. Interestingly, after 72 h viability sharply
decreased to 60% of UC (P0.001; Fig 1D).
DU145 and LNCaP cells treated with 4% NC-CC showed a significant, 30–40% reduction
in viability (P0.001; Fig 1B and 1C). Viability of PNT-2 cells was not affected by NC-CC after
Fig 1. Effect of NutramilTM Complex on cells viability. Cells of MCF-7 breast cancer line (A); DU145 prostate cancer line (B); LNCaP prostate cancer line
(C) and PNT-2 normal prostate line (D) were seeded on the 96-well plates (8x103 cells per well). 24 h after, growth medium was replaced with a medium
containing NutramilTM Complex (NC) or NutramilTM Complex without calcium caseinate (NC-CC) or calcium caseinate (CC) at concentration 0, 3, 4% for
24–72 h. Cell viability was measured with Cristal Violet (Sigma-Aldrich, Poland). Values are expressed as mean ± SD for n = 12, standardized to untreated
control (UC) as 100%. Statistical significance was based on t-test P0.01 vs. UC.
https://doi.org/10.1371/journal.pone.0192860.g001
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24 and 48 h, and decreased after 72 h by 30–35% (P0.001; Fig 1D). Treatment with calcium
caseinate cells showed a significant increase in cell viability across all tested cell lines (Fig 1A–
1D).
Cell proliferation
BrDU labeling results showed that NutramilTM Complex reduced the proliferation of studied
cell lines in a dose–and time–dependent manner. For MCF-7 breast cancer cells, proliferation
was reduced by approximately 30% at 48–72 h (P0.001, Fig 2A). Similar trend was observed
for the hormone-independent DU145 prostate cancer cell line, where proliferation decreased
by 40% at 72 h post-treatment (Fig 2B). Most prominent were results for LNCaP (androgen-
dependent) prostate cancer cells that showed the highest level of susceptibility to NC in our
study. Reduction in proliferation by 30% was observed already at 24–48 h and reached 40–
45% at 72 h post-treatment (Fig 2C). Interestingly, PNT-2 normal prostate cells reacted simi-
larly to cancer cells and showed approximately 30–40% reduction in proliferation after treat-
ment with NC (Fig 2D).
Results for NC-CC showed a similar trend to the NC treatment (Fig 2A–2C). Almost 30–
35% reduction in proliferation for MCF-7 and DU145 cell line (P0.001; Fig 2A and 2B) and
about 40% reduction after 72 h post-treatment for LNCaP cell line (P0.001; Fig 2C). On the
Fig 2. Effect of NutramilTM Complex on cells proliferation. MCF-7 breast cancer cells (A), DU145 prostate cancer cells (B), LNCaP prostate cancer cells (C)
and PNT-2 normal prostate cells (D) were seeded on the 96-well plates (8x103 cells per well). 24 h after seeding, growth medium was replaced with a medium
containing NutramilTM Complex (NC) or NutramilTM Complex without calcium caseinate (NC-CC) or calcium caseinate (CC) at concentration 0, 3, 4% for
24–72 h. Cell proliferation was measured using Cell Proliferation ELISA, BrdU (Roche, Poland). Values are expressed as mean ± SD for n = 12, standardized to
untreated control (UC) as 100%. Statistical significance was based on t-test P0.01 vs. UC.
https://doi.org/10.1371/journal.pone.0192860.g002
Effect of “NutramilTM Complex” on breast and prostate carcinoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0192860 February 14, 2018 6 / 19
other hand, proliferation of PNT-2 normal cell line significantly increased with time of treat-
ment (P0.001; Fig 2D).
Treatment with CC did not show statistically different results for proliferation of MCF-7
and PNT-2 cells vs UC (Fig 2A and 2D); however, it did not promote proliferation of prostate
cancer cells (Fig 2B and 2C).
mRNA expression of genes associated with cell cycle and apoptosis
To further evaluate the effect of NutramilTM Complex on studied cancer cell lines, we investi-
gated its effect on the expression of genes associated with cell cycle and apoptosis. Our analysis
showed that treatment with NC has an effect on mRNA levels of multiple genes. All results are
presented in Table 2.
For DU145, results showed down-regulation of anti-apoptotic AKT-1, BCL-2, HRAS,
IGF1R and some members of the YWHA family as well as up-regulation of many pro-apoptotic
genes, including APAF1, BAD, BAX, BID, CASP3, CASP8, CDKN2A, CYCS, FADD, FAS and
TP53.
For LNCaP cells, results showed down-regulation of anti-apoptotic HRAS, BCL-2, IGF1R,
KRAS, MYC, NRAS, RRAS and all members of the YWHA family as well as up-regulation of
APAF1, BAD, BAX, BID, CASP3, CASP8, CDKN2A, CYCS, FADD, FAS and TP53.
For MCF-7 breast cancer cells, data showed a significant decrease in the mRNA levels of
BCL-2, KRAS and NRAS oncogenes and some of the YWHA family. Pro-apoptotic genes,
including APAF1, CASP8, BID, BAD, BAX, and TP53 were up-regulated.
Similar trends were observed for treatment with NC-CC for all examined cell lines.
Expression of proteins involved in cellular stress and apoptosis signaling
PathScan1 Stress and Apoptosis Signaling Antibody Array analysis was performed for MCF-
7 (Fig 3A and 3B) and DU145 (Fig 4A and 4B) to further investigate the effect of NutramilTM
Complex on proteins involved in cellular stress, cell cycle and apoptosis signaling.
In addition, levels of Cytochrome c, Smac/Diablo and HtrA2/Omi mitochondrial proteins
were measured (Fig 5A and 5B).
For MCF-7 breast cancer cells, NutramilTM Complex reduced significantly the expression
of pro-survival AKT1 down to 82% of UC (P0.05; Fig 3B). The same trend was found for the
NC-CC treated cells (68% of UC, P0.05; Fig 3B). For pro-survival HSP27, results showed a
significant decrease in protein expression only for NC treated cells (60% of UC; P0.05; Fig
3A). No changes were measured for Survivin (Fig 3B). Results for TAK1 showed a significant
increase in the level of active protein form for both NC and NC-CC treated cells (209% and
194% of UC, respectively; P0.01; Fig 3A). NutramilTM Complex had a significant effect on
the p38 MAPK level (183% of UC; P0.05; Fig 3A) as well as on SAPK/JNK MAP (127% of
UC; P0.01; Fig 3A). Similar effects for both p38 MAPK and SAPK/JNK MAP were observed
for NC-CC (152% of UC and 161% of UC respectively; P0.01; Fig 3A). Significant increase of
total Iκβα was measured for both NC and NC-CC treated MCF-7 cells (309% of UC and 288%
of UC; P0.01; Fig 3A). However, results for NC showed a significant reduction in levels of
the phosphorylated form of Iκβα to 72% of NC (P0.05; Fig 3A). EIF-2α is the protein
required to initiate translation processes. Our results showed a slight increase in phosphory-
lated protein form in cells treated with both NC and NC-CC (both 121% of UC; P0.05; Fig
3A).
Our results showed strong activation of pro-apoptotic proteins in MCF-7 cells treated by
NutramilTM Complex, including p53 (128% of UC; P0.05; Fig 3B). Caspase-3 and Caspase-7
cleavage was significantly increased after NC treatment (177% and 150% of UC, respectively
Effect of “NutramilTM Complex” on breast and prostate carcinoma cells
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P0.05; Fig 3B). These results were also statistically significant for NC-CC, for which Caspase
-3 protein expression levels were 200% of UC (P0.01; Fig 3B). In addition, results showed an
increase in cleaved form of PARP after both NC and NC-C treatment (146% of UC and 124%
of UC, P0.01, respectively; Fig 3B). Our results also showed an increase in protein levels of
Cytochrome c, Smac/Diablo and HtrA2/Omi (Fig 5A), which promote caspases activity. The
effect of NC-CC on the expression of apoptosis markers was similar to that of NC (Fig 5A),
with the exception of HtrA2/Omi (Fig 5A). Chk1 and Chk2 kinases play an important role in
DNA damage checkpoint control. Results for both showed a significant increase in protein
expression levels after NC treatment (150% of UC and 237% of UC; P0.01; Fig 3B). Similar
Table 2. mRNA expression of genes associated with cell cycle and apoptosis in cancer cells.
Gene
Symbol
DU145 LNCaP MCF-7
NC vs UC NC-CC vs UC NC vs UC NC-CC vs UC NC vs UC NC-CC vs UC
FC value Adjusted
p-values
FC value Adjusted
p-values
FC value Adjusted
p-values
FC value Adjusted
p-values
FC value Adjusted
p-values
FC value Adjusted
p-values
AKT1 -1,36 0,03214 -1,04 0,00055 1,18 0,00081 -1,29 0,02324 1,44 0,00007 1,67 0,01273
APAF1 2,02 0,03147 -1,01 0,02270 2,54 0,00698 -2,28 0,00287 1,19 0,00024 -2,85 0,00000
BAD 2,29 0,01694 1,84 0,00439 2,38 0,00589 2,16 0,00880 2,46 0,00006 3,15 0,02347
BAX 3,67 0,01097 2,54 0,00087 2,88 0,00430 1,71 0,00779 1,62 0,00000 1,43 0,00035
BID 3,52 0,01590 2,04 0,00133 2,47 0,00474 1,35 0,32196 1,25 0,00005 1,21 0,00023
BCL2 -2,54 0,00431 -3,24 0,00000 -1,15 0,00474 -1,55 0,00312 -2,76 0,00160 -7,35 0,00018
CASP3 13,14 0,00003 6,07 0,00000 2,82 0,03960 -1,34 0,00876 Ns - Ns -
CASP8 5,68 0,00018 2,69 0,00053 3,05 0,00767 1,54 0,89843 2,23 0,00293 -1,14 0,00049
CDKN2A 3,23 0,00020 2,29 0,00008 3,00 0,00023 1,96 0,02395 Ns - Ns -
CYCS 4,82 0,00908 2,70 0,00007 1,81 0,00112 1,95 0,00007 -3,11 0,00006 -4,47 0,00001
FADD 4,72 0,00174 2,47 0,00096 2,80 0,00072 -1,71 0,00178 2,30 0,00003 1,92 0,01687
FAS 5,20 0,01975 1,28 0,30215 3,02 0,02340 1,70 0,00566 -2,67 0,00233 -4,87 0,00002
HRAS -1,42 0,68056 -1,03 0,00173 -1,47 0,00041 -2,04 0,00554 1,28 0,00000 1,35 0,00097
IGF1R -1,12 0,00309 -1,41 0,00114 -1,06 0,00027 -1,81 0,00106 2,09 0,00001 1,49 0,00044
KRAS 2,85 0,00005 1,43 0,00010 -1,08 0,01581 -2,11 0,00009 -1,15 0,00005 -3,45 0,00026
MYC 1,03 0,00907 1,03 0,00032 -1,21 0,00120 1,13 0,01434 2,83 0,00011 2,00 0,01215
NRAS 2,04 0,00007 1,27 0,00047 -1,24 0,01742 -1,87 0,00803 -1,38 0,00002 -4,53 0,00001
RRAS -1,25 0,58008 -1,35 0,07026 -1,47 0,03462 -1,48 0,07072 1,89 0,00047 1,83 0,01436
TP53 1,20 0,27491 1,21 0,00218 2,70 0,00292 1,02 0,28757 2,07 0,00000 1,94 0,00606
YWHAB -1,06 0,00153 1,03 0,00014 -1,31 0,00269 -1,03 0,52029 1,50 0,00001 1,04 0,00017
YWHAE 1,38 0,00004 1,28 0,00000 -1,37 0,00001 -1,82 0,00639 -1,39 0,00000 -3,66 0,00000
YWHAG -1,07 0,02792 1,02 0,01573 -1,55 0,00759 -1,36 0,25445 2,51 0,00133 1,58 0,01705
YWHAH -1,17 0,04692 -1,08 0,02815 -1,48 0,00188 -1,56 0,08087 1,13 0,00055 -1,31 0,00166
YWHAQ 1,15 0,00036 1,06 0,00049 -1,32 0,00222 -1,55 0,00328 -1,03 0,00000 -3,06 0,00000
YWHAZ 1,43 0,00043 1,13 0,00279 -1,50 0,00172 -2,14 0,00291 1,36 0,00014 -2,92 0,00001
AKT1, Serine/Threonine Kinase 1; APAF1, Apoptotic Peptidase Activating Factor 1; BAD, Bcl2-Associated Agonist Of Cell Death; BAX, BCL2 Associated X, Apoptosis
Regulator; BID, BH3 Interacting Domain Death Agonist, CASP3, Caspase 3; CASP8, Caspase 8; CDKN2A, Cyclin Dependent Kinase Inhibitor 2A; CYCS, Cytochrome C;
FADD, Fas- Associated Death Domain; FAS, Fas Cell Surface Death Receptor; HRAS, HRas Proto-Oncogene, GTPase; IGF1R, Insulin Like Growth Factor 1 Receptor;
KRAS, KRAS Proto-Oncogene, GTPase; MYC, MYC Proto-Oncogene, BHLH Transcription Factor; NRAS, NRAS Proto-Oncogene, GTPase; RRAS, Related RAS Viral
(R-Ras) Oncogene Homolog; TP53, Tumor Protein P53; YWHAB, Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Beta; YWHAE,
Tyrosine 3Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon; YWHAG, Tyrosine 3Monooxygenase/Tryptophan 5-Monooxygenase Activation
Protein Gamma; YWHAH, Tyrosine 3Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Eta; YWHAQ, Tyrosine 3Monooxygenase/Tryptophan
5-Monooxygenase Activation Theta; YWHAZ Tyrosine 3Monooxygenase/Tryptophan 5-Monooxygenase Activation Zeta.
Ns, no signal; Statistical significance of treatment: P0.05.
https://doi.org/10.1371/journal.pone.0192860.t002
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trend was observed for NC-CC treated cells (113% of UC and 230% of UC, respectively Fig
3B).
For DU145 cells, treatment with NutramilTM Complex reduced the level of pro-survival
proteins such as ERK1/2 to 63% of UC (P0.05; Fig 4A), AKT1 to 70% of UC (P0.05; Fig
4B), HSP27 to 83% of UC (NS; Fig 4A), Survivin to 78% of UC (P0.01; Fig 4B), phospho-
BAD to 90% of UC (NS; Fig 4B) and phospho-Iκβα to 81% of UC (P0.05; Fig 4A). Expres-
sion of TAK1 was increased to 204% of UC (P0.05; Fig 4A). On the other hand, the expres-
sion of pro-apoptotic proteins, p53 and SMAD-2, was increased (124% and 134% of UC,
respectively; P0.05; Fig 4B). Caspase-3 and Caspase-7 cleavage was found increased to 167%
and 150% of UC respectively (P0.01; Fig 4B). In addition, results also showed increased levels
of cleaved PARP cleavage (250% of UC; P0.01; Fig 4B) as well as mitochondrial Cytochrome
Fig 3. Expression of proteins involved in cellular stress and apoptosis signaling in MCF-7 breast cancer cells.
https://doi.org/10.1371/journal.pone.0192860.g003
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Fig 4. Expression of proteins involved in cellular stress and apoptosis signaling in DU145 prostate cancer cells.
MCF-7 breast cancer (Fig 3) and DU145 prostate cancer (Fig 4) cells were treated for 48 h with NC, NutramilTM
Complex, at 4% concentration; NC-CC, NutramilTM Complex without calcium caseinate, at 4% concentration or ST,
staurosporine positive control, at 1.5 μM concentration. Cell extracts were prepared and analyzed using the
PathScan1 Stress and Apoptosis Signaling Antibody Array Kit (Chemiluminescent Readout; #12856, Cell Signaling
Technology, MA, USA). Images were acquired by briefly exposing the slide to standard chemiluminescent film.
Densitometry analysis was performed using ImageJ. Results are shown as a mean±SD normalized to the internal
reference protein (α-Tubulin). Untreated negative control (NC) was set as 100% expression level. Statistical
significance of NC was based on t-test p0.05 vs. UC. (A)Proteins involved in cellular stress response. P44/42 MAPK
(ERK1/2) phosphorylation (Thr202/Tyr204), HSP27 phosphorylation (Ser82), p38 MAPK phosphorylation (Thr180/
Tyr182), SAPK/JNK phosphorylation (Thr183/Tyr185), IkB total, IkBα phosphorylation (Ser32/36), eIF-2α
phosphorylation (Ser51), TAK1 phosphorylation (Ser412).(B)Proteins involved in cell cycle and apoptosis signaling.
AKT phosphorylation (Ser473), Survivin total, BAD phosphorylation (Ser136), SMAD-2 phosphorylation (Ser465/
467), p53 phosphorylation (Ser15), PARP cleavage (Asp214), Caspase-3 cleavage (Asp175), Caspase-7 cleavage
(Asp198), Chk1 phosphorylation (Ser345), Chk2 phosphorylation (Thr68).
https://doi.org/10.1371/journal.pone.0192860.g004
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c and HtrA2/Omi (Fig 5B). Total Iκβα increased to 158% of UC (P0.05; Fig 4A), p38 MAPK
to 146% of UC (P0.05; Fig 4A) and SAPK/JNK to 130% of UC (P0.05; Fig 3B). Significant
increase in protein expression was found for Chk2 (272% of UC; P0.01; Fig 4A); however,
NC had no measurable effect on Chk1 level (99% of UC; Fig 4B). EIF-2α protein expression
was 119% of UC after NC treatment (P0.05; Fig 4A).
The effect of the NutramilTM formulation without calcium caseinate on pro-survival pro-
teins was similar to that of NC (Fig 4A and 4B). Down-regulation in protein levels was
Fig 5. Expression of Cytochrome c, Smac/Diablo and HtrA2/Omi in cancer cells. MCF-7 breast cancer (A) and
DU145 prostate cancer (B) cells were treated for 48 h with NC, NutramilTM Complex, at 4% concentration; NC-CC,
NutramilTM Complex without calcium caseinate, at 4% concentration; or ST, staurosporine positive control, at 1.5 μM
concentration. Cell extracts were prepared using Cell Lysis Buffer (Cell Signaling Technology, MA, USA) with the
addition of Protease Inhibitor Cocktail (BioShop, Canada). Protein extracts were then separated on a polyacrylamide
gel and transferred to a nitrocellulose filter (Bio-Rad, CA, USA) by wet-electroblotting. The immobilized proteins were
incubated with Cytochrome c (#11940), Smac/Diablo (#2954), and HtrA2/Omi (#9745) primary antibody (Cell
Signaling Technology, MA, USA). β-Tubulin (#2128, Cell Signaling Technology, MA, USA) was used as a reference
protein. Detection was executed by chemiluminescence, using Clarity™ Western ECL Substrate (Bio-Rad, CA, USA).
https://doi.org/10.1371/journal.pone.0192860.g005
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measured for ERK1/2 (73% of UC; P0.05; Fig 4A), AKT1 (82% of UC; P0.05; Fig 4B),
HSP27 (77% of UC; NS; Fig 4A), phospho-Iκβα (66% of UC; P0.05; Fig 4A) as well as up-reg-
ulation of TAK1 (322% of UC; P0.05; Fig 4A) and phospho-BAD (165% of UC; P0.05; Fig
4B). The effect of NC-CC on the expression of pro-apoptotic proteins was stronger than of NC
(Fig 5B), again with the exception of HtrA2/Omi (Fig 5B). Expression of tumor suppressors
p53 and SMAD-2 increased respectively to 302% and 198% of UC (P0.01; Fig 4B); levels of
Caspase-3 cleavage increased to 211%, Caspase-7 cleavage to 234% and PARP cleavage to
290% of UC (P0.01; Fig 4B). Similarly, results showed an increase in expression of p38
MAPK (182% of UC; P0.05; Fig 4A), SAPK/JNK (237% of UC; P0.05; Fig 4A) as well as
total Iκβα (318% of UC; (P0.01; Fig 4A). Finally, NC-CC treatment resulted in upregulation
of Chk1 and Chk2 kinases (199% and 453% of UC, respectively; P0.01; Fig 4B) and eIF-2α
(211% of UC; P0.01; Fig 4A). NC-CC treatment did not seem to have any effect on Survivin
levels (101% of UC; Fig 4B).
Discussion
NutramilTM Complex is a complete nutritional supplement, providing about 417 kcal/100 g
from 60% carbohydrate, 25% fat and 15% protein. It was designed to contain all essential
nutrients i.e. basic nutrients, minerals and vitamins in balanced proportions as required by
dietary recommendations. The high-quality protein is delivered in the form of calcium casein-
ate, which is a milk protein. Carbohydrates, including sugars, are supplied in form of maize
maltodextrin with varying absorption rates. The product is clinically free of lactose. As sources
of fats include: rapeseed oil (80%) and medium-chain triglycerides (MCTs) (20%). It provides
very important mono-unsaturated oleic acid, essential fatty acids, as well as long-chain triglyc-
erides (LCTs). MCTs provide fast and lasting energy and are easily absorbed by the body. In
addition, they also have a positive effect on calcium absorption.
In our previous pilot studies, we have shown that NutramilTM Complex decreases the via-
bility of breast and prostate cancer cells [7, 8]. In current manuscript, we made an attempt to
determine the potential molecular mechanism after treatment with NC (Figs 1A–1C and 2A–
2C). To examine whether the apoptosis was the primary cause of cell death, we analysed the
levels of genes associated with apoptotic events. Further, we verified the effect of NC on
selected proteins involved in cellular stress signalling related to apoptosis induction (Fig 6).
Our results for NC treated cancer cells showed an increased expression of TP53 in all exam-
ined cell lines. We also measured promoted expression of CDKN2A in prostate cancer lines
(Table 2). The TP53 gene is a key cancer suppressor gene. The p53 protein controls the tran-
scription of many different genes in response to stress signals, thus regulating processes related
to DNA repair, cell-cycle arrest or apoptosis. In turn, the CDKN2A codes for p16 and p14ARF
proteins that act via two independent pathways: retinoblastoma RB- and p53- tumour suppres-
sor pathways, respectively [10]. Chk1 and Chk2 play an important role in DNA damage check-
point control (Fig 6). They also affect the post-translation modifications of p53 protein,
leading to its accumulation [11]. Our results confirm over-expression of p53 protein after NC
treatment (Figs 3B and 4B) as well as an increase in Chk1 and Chk2 protein expression (Figs
3B and 4B). As a transcription factor, p53 is responsible, among others, for the regulation of
mitochondrial-induced pro-apoptotic proteins of BCL-2 family [12,13]. BCL-2 is a family of
proteins regulating the apoptosis processes by controlling the mitochondrial permeability [14].
Our results showed that NC increased gene expression of pro-apoptotic BAX, BID, BAD mem-
bers, and decreased expression of anti-apoptotic BCL-2 (Table 2). In addition, we determined
up-regulation of APAF1 and CYCS genes (Table 2), which encodes a cytoplasmic protein that
initiates apoptosis (Fig 5). Apaf-1 protein is a caspase-activating molecule that is released from
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the mitochondria during apoptosis induction. Activation of p53 results in oligomerization of
pro-apoptotic members (BAX, BID, PUMA, NOXA) at the mitochondrial outer membrane
and translocation of Cytochrome c and Apaf-1 into cytosol followed by activation of Caspases
[15]. The Caspase-3 and Caspase-7 are the downstream effector caspases that cleave specific
cellular targets. PARP is one of the earliest nuclear enzymes to be targeted by Caspase-3 during
apoptosis [16]. In our study, we confirmed the activation of pro-apoptotic markers (Cyto-
chrom c, Smac/Diablo, HtrA2/Omi) as well as Caspase-3 and 7 under NC (Figs 3B, 4B, 5A and
5B). We also measured an increased level of cleaved form of PARP (Figs 3B and 4B).
In our work, we also verified the impact of NC on selected proteins involved in cellular
stress response and their links to apoptosis induction (Fig 6). Our results showed that NC
treatment decreased expression of ERK1/2 (Fig 4A) and AKT1 (Fig 4B) proteins in prostate
cancer cells and AKT1 and HSP27 cells in MCF-7 cells (Fig 3A and 3B). AKT kinase is a major
signaling node that transmit signals related to many essential pro-survival cellular functions.
The main consequence of its activation is increased proliferation and tumor transformation
and inhibition of apoptosis [17,18]. In addition, AKT phosphorylated the pro-apoptotic BAD
protein at Ser136 and inhibits its ability to induce apoptosis [19,20]. HSP27 is a mediator of
Fig 6. Mechanism of NC induced apoptosis in cancer cells.
https://doi.org/10.1371/journal.pone.0192860.g006
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cellular stress that confers resistance to adverse environmental conditions. It was associated
with the inhibition of Cytochrome c release from mitochondria and with an increase in AKT
expression [21].
Our results showed a significantly elevated level of phosphorylated p38 MAPK and SAPK/
JNK MAP kinases in both MCF-7 and DU145 cell lines after the treatment with NC (Figs 3A
and 4A). Activation of p38 MAPK and SAPK/JNK MAP kinases occurs via dual phosphoryla-
tion mechanism in response to cellular stressors and leads to regulation of the inflammatory
response, cell-cycle arrest and apoptosis induction. It has been suggested that SAPK/JNK can
contribute to the both, the c-Jun / AP-1 external apoptosis pathway as well as to the mitochon-
dria-dependent apoptosis pathway via p53 and pro-apoptotic BCL-2 family activation. In addi-
tion, the suggestion was made that these mechanisms can act independently or co-operate
with one another to induce cell death [22]. Our results give support to this hypothesis as they
showed an increased expression of FADD and CASP 8 genes in both breast and prostate cancer
cell lines and for the prostate cell lines also of FAS gene, associated with the external apoptosis
pathway (Table 2).
Our results showed also an increase in MYC mRNA expression in both MCF-7 and DU145
lines, while its down-regulation in LNCaP (Table 2). MYC expression is closely associated with
the progression of cell-cycle in normal tissues and its overexpression has been found in variety
of cancer types. Interestingly, increasing number of research shows that MYC can be also
involved in the control of apoptosis. McMahon [15] in his review points out that for normal
cells when growth factors are limiting, cells with high MYC levels may activate p53 protein,
leading to the induction of apoptotic events. However, in the absence of p53 activation and /
or pre-dominance of pro-life factors such as BCL-2, high MYC expression may be insufficient
to trigger apoptosis. Our results, demonstrated overexpression of MYC, p53 accumulation as
well as lowered levels of BCL-2 expression, supporting this hypothesis.
In our study, we also investigated the effect of NC on the activity of Iκβα. Iκβα protein reg-
ulates the activity of NF-κβ transcription factor by forming a protein complex that prevents
translocation of NF-κβ to the nucleus. Presence of phosphorylated form of Iκβα indicates the
degradation of the NF-κβ / Iκβα complex and translocation of NF-κβ into the nucleus, where
as a transcription factor it can activate many pro- or anti-apoptotic genes [23]. Treatment with
NutramilTM Complex significantly increased the level of un-phosphorylated Iκβα, capable of
binding to NF-κβ (Figs 3A and 4A). Interestingly, our results showed elevated level of TAK1
protein, which may promote phosphorylation of Iκβα protein [24] while measuring lower lev-
els of phosphorylated Iκβα after NC treatment (Figs 3A and 4A).
Many studies are available on individual components of NutramilTM Complex that show
their potential anti-cancer properties. For MCT fats, they have been shown to delay tumour
growth in a mouse xenograft model [25] and to exacerbate the therapeutic effect of studied
anti-cancer substances in TCC cells in dogs [26]. Similarly, rape seeds have been shown to
exhibit very strong antioxidant activity and have the potential to inhibit the proliferation of
tumour cells [27, 28]. Studies in MCF-7 and T47D breast lines showed their inhibitory effect
on cancer cell growth leading to induction of apoptosis via increased expression of Caspase-3
and p53 [29]. In the in vivo studies, canola oil diet significantly reduced the incidence as well
as multiplicity of colorectal tumours in rats [30].
NutramilTM Complex contains all vitamins and minerals, including macronutrients and
micronutrients essential for proper functioning of the human body (S1 Table). Some of
them, including vitamin D, C, K, E, B complex vitamins and minerals, i.e. selenium, zinc
and iodine, have proven anti-tumour activity [31–33]. Deeb et al. [34] have demonstrated
that the active form of vitamin D3 (1α, 25 (OH) 2D3) exhibits anti-tumour properties by
regulating the expression of Bcl-2 family proteins and by activating the Caspases. Vitamin
Effect of “NutramilTM Complex” on breast and prostate carcinoma cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0192860 February 14, 2018 14 / 19
D3 in NutramilTM is in the form of cholecalciferol, thus the pro-apoptotic effect of 1α,25
(OH)2D3 may not be directly translated into the observed properties of the formulation;
however, some studies suggest that cholecalciferol may be metabolized in some tumour
cells, especially in breast cancer cells [35]. Studies in vitro on lymphoma cells using ascorbic
acid (form of vitamin C present in NutramilTM Complex) showed a decrease in the viability
of cancer cells without affecting normal cells [36]. In turn, vitamin K affects the levels of
tyrosine kinases, phosphatases and activation of transcription factors Myc and Fos, followed
by the regulation of expression of genes involved in cell cycle regulation and apoptosis
induction [37].
For B complex vitamins, deficiencies in B6 and B12 can cause DNA damage and lead to can-
cer [38, 39]. Riboflavin reduces the risk of cancer by acting as a cofactor in folate metabolism
[40] and by enhancing the anti-cancer activity of vitamin C [41]. The effect of thiamine supple-
mentation is not yet fully understood. On the one hand, it has been shown that thiamine can
enhance cancer cell proliferation and increase therapeutic resistance [42, 43]; on the other
hand, a high dose of this vitamin has been shown to have an inhibitory effect on tumour cell
growth [42, 44]. Vitamin E includes a vast group of compounds belonging to the tocopherols
and tocotrienols family, which have been shown to have anti-tumour properties [45]. It has
been shown that some vitamin E components such as RRR-alpha-tocopheryl succinate and
tocopherol ether may have pro-apoptotic effect on cancer cells in a dose that does not affect
healthy cells [46]. However, there are no reports linking the DL-α-tocopheryl acetate, which is
an active vitamin E form in the NutramilTM Complex, with reduced survival of cancer cells.
Another component of NutramilTM Complex is the sodium selenite, which anti-tumor proper-
ties have been demonstrated in animals [47] and in cell lines including fibrosarcoma, lung car-
cinoma and acute promyelocytic leukemia [48–51]. One of in vivo studies involved nude mice
bearing human colorectal carcinoma SW480 cell line xenografts, which were injected peritone-
ally for 21 days with sodium selenite. Results showed significant tumour suppression. In addi-
tion, authors showed reduced expression of Bcl-xL proteins and increased expression of pro-
apoptotic proteins, including Bax, Bad and Bim as well as Caspase-9 [47]. In studies using
U2OS cells, induction of apoptosis has been shown to be associated with activation of Caspase-
3, up-regulation of TP53 and PTEN suppressors and down-regulation of BCl-2 expression. In
promyelocytic leukemia NB4 cells, sodium selenite induced reactive oxygen species generation
that was associated with early events that triggers endoplasmic reticulum stress mitochondrial
apoptotic pathways [51]. Finally, for A549 human lung carcinoma cells, sodium selenite has
been shown to modulate both extrinsic and intrinsic apoptotic pathways. Apoptosis induction
was mediated by reactive oxygen species (ROS) and was dependent on the activation of Cas-
pases [49].
Zinc whose anti-neoplastic properties have been described for breast cancer cells and pros-
tate cancer [52] is also present in the formulation. In both cell lines, apoptosis was associated
with the mitochondrial pathway, including events such as activation of pro-apoptotic BAX,
Cytochrome c translocation and Caspase activation. In breast cancer cells (MCF-7) induction
of apoptosis was accompanied by accumulation of p53 protein [53], whereas in PC-3 prostate
cancer cells, apoptosis was independent of p53, but also via the mitochondrial pathway [52,
54]. Another mineral ingredient of the NutramilTM formulation with potential anti-neoplastic
significance is magnesium. This element participates in many metabolic processes and redox
reactions [55]. Magnesium present in drinking water was associated with reduction of the risk
of liver cancer [56], while high-dose magnesium supplementation was shown to reduce the
risk of colorectal cancer [57]. Epidemiological studies confirm the relationship between mag-
nesium deficiency and colorectal cancer in overweight people [58]. It is also worth mentioning
the role of calcium ions in regulation of proliferation and induction of apoptosis. Regulation of
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calcium ion concentration is dependent on activation of ion channels, including K+ and Cl-
channels, that regulate the membrane potential and increase the probability of Ca2+ channel
opening. Also, the activity of individual ions affects their concentration in the cytoplasm [59].
The correlation has been shown between deregulation of these ions and apoptosis. Increasing
intracellular chloride and sodium ion concentrations results in increased ROS, release of Cyto-
chrome c into the cytoplasm and cell apoptosis [60]. Finally, among the listed mineral compo-
nents of the preparation, iodine also has been shown to have a pro-apoptotic activity on breast
cancer (MCF-7) [61].
In conclusion, our study, as one of very few, show the effect of complete food medical
supplement on cancer cells. It is well known that cells integrate multiple signals from a vari-
ety of sources before following either pro- or anti-apoptotic pathway. Taking into account
the significant reduction if cancer cell growth (Figs 1A–1C and 2A–2C) with simultaneous
activation of many pro-apoptotic proteins, tumour suppressors and regulators of cell-cycle
(Figs 3A, 3B, 4A. 4B, 5A and 4B and Table 2), it can be concluded that NutramilTM Complex
exhibits anti-tumor properties. Moreover, our data suggest that it activates apoptotic events
via mitochondrial-induced pathway (Fig 6). This is most likely related to the composition of
the preparation: the optimum proportion, bioavailability and cellular metabolism of the
individual components. It appears that NutramilTM Complex as a Food for Special Medical
Purpose can support the treatment of oncological patients, not only due to their complete
nutritional value, but also for the cytotoxic effects on tumour cells. We admit that our
results are based on the in vitro model which requires further verification in vivo; However,
according to the 3R principles (Replacement, Reduction and Refinement), the in vitro stud-
ies are a valuable and multi-faceted source of information and may explain the adequacy of
further in vivo research.
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